Jameelah Robinson

  • Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during a Bloomberg Television interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S’s obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said. Photographer: Christopher Goodney/Bloomberg via Getty ImagesHealth

    Weight-loss stocks soar up to 15% after obesity-drug study shows an added benefit that may be a ‘huge win’ for future sales

    By Angel Adegbesan, Jameelah Robinson, and others